[Clinical Characteristics, Treatment and Prognosis of 47 Non-small Cell Lung Cancer with Neuroendocrine Differentiation Patients].
Journal: 2019/August - Chinese Journal of Lung Cancer
ISSN: 1999-6187
Abstract:
Non-small cell lung cancer (NSCLC) with neuroendocrine differentiation (NED) was a new pathologic type and uncommon in clinics. The aim of this study is to observe the relationship between clinical pathologic characteristics, imagination, biological behavior and prognosis in NSCLC-NED.The clinical data of 47 patients with NSCLC-NED admitted from January 2009 to November 2017 in the Fifth Medical Center of General Hospital of People's Liberation Army were collected. The demographic data and imaging characteristics were summarized. Pathological features, treatment and prognosis, analysis of the correlation between different factors and prognosis.Of the 47 patients with NSCLC-NED, the median age was 61 years (45 years-78 years), 38 males and 9 females; 37 were poorly differentiated cancer with NED, and 10 were middle differentiated cancer with NED; 2 cases of driving gene positive (1 case of EGFR sensitive mutation, 1 case of ALK fusion), objective response rate (ORR) of first-line chemotherapy was 34.5%, and median progression-free survival (PFS) was 4 months; the median overall survival (OS) was 11 months, and only 2 cases (4.2%, 2/47) of OS were over 2 years.NSCLC-NED is different from simple NSCLC or pulmonary neuroendocrine tumors. Males, ≤70 years old, severely smoking, and patients with lower tumor differentiation often have NED, and most of them are stage IV. This type of patient-driven gene positive proportion is lower than the general adenocarcinoma population, less sensitive to chemotherapy, and the overall survival is shorter, indicating a poor prognosis.
Relations:
Content
Citations
(1)
References
(9)
Diseases
(3)
Genes
(1)
Processes
(1)
Anatomy
(1)
Affiliates
(2)
Similar articles
Articles by the same authors
Discussion board
Zhongguo Fei Ai Za Zhi 22(8): 507-511

47例非小细胞肺癌伴神经内分泌分化的临床特点、治疗及预后

背景与目的

非小细胞肺癌(non-small cell lung cancer, NSCLC)伴神经内分泌分化(neuroendocrine differentiation, NED)是一个新的病理分类,在临床中并不常见,本文拟探讨NSCLC-NED的临床病理特征、影像学特点、治疗及预后。

方法

收集解放军总医院第五医学中心2009年1月-2017年11月期间收治的47例NSCLC-NED患者的临床资料,总结其人口学资料、影像学特点、病理特征及治疗和预后,分析不同因素与预后之间的相关性。

结果

47例NSCLC-NED患者中,中位年龄61岁(45岁-78岁),男性38例,女性9例; 37例为低分化癌伴NED,10例为中分化癌伴NED; 2例驱动基因阳性(1例为EGFR敏感突变,1例为ALK融合),一线化疗的客观有效率(objective response rate, ORR)为34.5%,中位无进展生存期(progression-free survival, PFS)为4个月; 整体中位总生存期(overall survival, OS)为11个月,OS超过2年者仅2例(4.2%, 2/47)。

结论

NSCLC-NED不同于单纯的NSCLC或肺神经内分泌肿瘤,男性、≤70岁、重度吸烟、肿瘤分化程度较低者较常出现NED,且发病时多为Ⅳ期。该类患者驱动基因阳性比例低于普通腺癌人群,对化疗较不敏感,总生存期偏短,提示预后较差。

Background and objective

Non-small cell lung cancer (NSCLC) with neuroendocrine differentiation (NED) was a new pathologic type and uncommon in clinics. The aim of this study is to observe the relationship between clinical pathologic characteristics, imagination, biological behavior and prognosis in NSCLC-NED.

Methods

The clinical data of 47 patients with NSCLC-NED admitted from January 2009 to November 2017 in the Fifth Medical Center of General Hospital of People's Liberation Army were collected. The demographic data and imaging characteristics were summarized. Pathological features, treatment and prognosis, analysis of the correlation between different factors and prognosis.

Results

Of the 47 patients with NSCLC-NED, the median age was 61 years (45 years-78 years), 38 males and 9 females; 37 were poorly differentiated cancer with NED, and 10 were middle differentiated cancer with NED; 2 cases of driving gene positive (1 case of EGFR sensitive mutation, 1 case of ALK fusion), objective response rate (ORR) of first-line chemotherapy was 34.5%, and median progression-free survival (PFS) was 4 months; the median overall survival (OS) was 11 months, and only 2 cases (4.2%, 2/47) of OS were over 2 years.

Conclusion

NSCLC-NED is different from simple NSCLC or pulmonary neuroendocrine tumors. Males, ≤70 years old, severely smoking, and patients with lower tumor differentiation often have NED, and most of them are stage Ⅳ. This type of patient-driven gene positive proportion is lower than the general adenocarcinoma population, less sensitive to chemotherapy, and the overall survival is shorter, indicating a poor prognosis.

100070 北京,首都医科大学附属北京天坛医院肿瘤综合治疗病区, Department of Oncologic Comprehensive Therapy, Beijing Tiantan Hospital, Capital Medical University, Beijing 100070, China,
100071 北京,解放军总医院第五医学中心肺部肿瘤科, Department of Lung Cancer, The Fifth Medical Center, General Hospital of People's Liberation Army, Beijing 100071, China,
李 晓燕 (Xiaoyan LI): moc.621@ahrerahs
李晓燕, Xiaoyan LI, E-mail: moc.621@ahrerahs
李 晓燕 (Xiaoyan LI): moc.621@ahrerahs
Received 2018 Nov 30; Revised 2019 Jan 12; Accepted 2019 Jan 16.

Abstract

背景与目的

非小细胞肺癌(non-small cell lung cancer, NSCLC)伴神经内分泌分化(neuroendocrine differentiation, NED)是一个新的病理分类,在临床中并不常见,本文拟探讨NSCLC-NED的临床病理特征、影像学特点、治疗及预后。

方法

收集解放军总医院第五医学中心2009年1月-2017年11月期间收治的47例NSCLC-NED患者的临床资料,总结其人口学资料、影像学特点、病理特征及治疗和预后,分析不同因素与预后之间的相关性。

结果

47例NSCLC-NED患者中,中位年龄61岁(45岁-78岁),男性38例,女性9例; 37例为低分化癌伴NED,10例为中分化癌伴NED; 2例驱动基因阳性(1例为EGFR敏感突变,1例为ALK融合),一线化疗的客观有效率(objective response rate, ORR)为34.5%,中位无进展生存期(progression-free survival, PFS)为4个月; 整体中位总生存期(overall survival, OS)为11个月,OS超过2年者仅2例(4.2%, 2/47)。

结论

NSCLC-NED不同于单纯的NSCLC或肺神经内分泌肿瘤,男性、≤70岁、重度吸烟、肿瘤分化程度较低者较常出现NED,且发病时多为Ⅳ期。该类患者驱动基因阳性比例低于普通腺癌人群,对化疗较不敏感,总生存期偏短,提示预后较差。

Keywords: 肺肿瘤, 神经内分泌分化, 驱动基因, 预后
Abstract

Abstract

Background and objective

Non-small cell lung cancer (NSCLC) with neuroendocrine differentiation (NED) was a new pathologic type and uncommon in clinics. The aim of this study is to observe the relationship between clinical pathologic characteristics, imagination, biological behavior and prognosis in NSCLC-NED.

Methods

The clinical data of 47 patients with NSCLC-NED admitted from January 2009 to November 2017 in the Fifth Medical Center of General Hospital of People's Liberation Army were collected. The demographic data and imaging characteristics were summarized. Pathological features, treatment and prognosis, analysis of the correlation between different factors and prognosis.

Results

Of the 47 patients with NSCLC-NED, the median age was 61 years (45 years-78 years), 38 males and 9 females; 37 were poorly differentiated cancer with NED, and 10 were middle differentiated cancer with NED; 2 cases of driving gene positive (1 case of EGFR sensitive mutation, 1 case of ALK fusion), objective response rate (ORR) of first-line chemotherapy was 34.5%, and median progression-free survival (PFS) was 4 months; the median overall survival (OS) was 11 months, and only 2 cases (4.2%, 2/47) of OS were over 2 years.

Conclusion

NSCLC-NED is different from simple NSCLC or pulmonary neuroendocrine tumors. Males, ≤70 years old, severely smoking, and patients with lower tumor differentiation often have NED, and most of them are stage Ⅳ. This type of patient-driven gene positive proportion is lower than the general adenocarcinoma population, less sensitive to chemotherapy, and the overall survival is shorter, indicating a poor prognosis.

Keywords: Lung neoplasms, Neuroendocrine differentiation, Driver gene, Prognosis
Abstract

按照组织病理学分类,非小细胞肺癌(non-small cell lung cancer, NSCLC)占原发性肺癌的80%-85%,主要分为腺癌、鳞癌、腺鳞混合型或大细胞癌1],其中,1999年世界卫生组织(World Health Organization, WHO)病理分期特别提出一个新的分类:NSCLC伴神经内分泌分化(neuroendocrine differentiation, NED),指的是:除经典的肺神经内分泌肿瘤(neuroendocrine lung tumor, NELT)外,NSCLC中存在部分肿瘤,虽然不具有光镜下典型的NE细胞形态特点,但相关NED标记物染色阳性并且在电镜下可见细胞内的NED颗粒,表现出同经典NELT相似的特性。WHO将这部分具有NED分化的NSCLC归为Ⅱ类NELT2]。这一病理亚型不同于单纯的NSCLC或肺神经内分泌肿瘤,但在临床实践中对不具有典型光镜下NED形态结构的NSCLC不常规进行相关NED免疫组化染色,导致人们对这一类肿瘤的诊断、治疗及预后认识不足。

本研究通过对47例伴NED的NSCLC病例进行回顾性分析,总结其临床特征、影像学及病理特点,并分析其与治疗和预后的相关性。

Competing interests

The authors declare that they have no competing interests.

Competing interests
Competing interests

References

  • 1. Ramalingam SS, Owonikoko TK, Khuri FRLung cancer: New biological insights and recent therapeutic advances. CA Cancer J Clin. 2011;61(2):91–112. doi: 10.3322/caac.20102.] [[PubMed][Google Scholar]
  • 2. Gibbs AR, Thunnissen FBHistological typing of lung and pleural tumours: third edition. J Clin Pathol. 2001;54(7):498–499. doi: 10.1136/jcp.54.7.498.] [[Google Scholar]
  • 3. Langfort R, Runzifiski P, Burakowska B. Pulmonary neuroendocrine tumors. The spectrum of histologic subtypes and current concept on diagnosis and treatment. Pneumonol Alergolo Pol. 2010;78(1):33–46.[PubMed]
  • 4. Sterlacci W, Fiegl M, Veits L, et al Diagnostic and prognostic impact of mucin 1-6 expression in non-small cell lung cancer. Indian J Pathol Microbiol. 2018;61(2):187–191. doi: 10.4103/IJPM.IJPM_678_17.] [[PubMed][Google Scholar]
  • 5. Segawa Y, Takata S, Fujii M, et al Immunohistochemical detection of neuroendocrine differentiation in non-small-cell lung cancer and its clinical implications. J Cancer Res Clin Oncol. 2009;135(8):1055–1059. doi: 10.1007/s00432-009-0544-1.] [[PubMed][Google Scholar]
  • 6. Sundaresan V, Reeve JG, Stenning S, et al Neuroendocrine differentiation and clinical behaviour in non-small cell lung tumours. Br J Cancer. 1991;64(2):333–338. doi: 10.1016/0169-5002(91)91529-K.] [[Google Scholar]
  • 7. Liu Y, Xu ML, Wang J, et al The relationship between neuroendocrine differentiated expression and gene of apoptosis in non-small cell lung cancer. Tianjin Yi Yao. 2008;12(9):919–922.刘 岩, 徐 美林, 王 菁, et al. 非小细胞肺癌凋亡相关基因与神经内分泌分化表达的研究 天津医药 2008;12(9):919–922. doi: 10.3969/j.issn.0253-9896.[PubMed][Google Scholar]
  • 8. Zhao P, Hou N, Shao Y, et al Clinicopathological significance of expression of c-kit protein in neuroendocrine lung carcinoma. Zhonghua Yi Xue Za Zhi. 2005;22(9):1526–1529.赵 坡, 侯 宁, 邵 云, et al. 肺神经内分泌癌c-kit蛋白表达的临床病理意义 中华医学杂志 2005;22(9):1526–1529. doi: 10.3760/j:issn:0376-2491.[PubMed][Google Scholar]
  • 9. Petrovi M, Baski D, Bankovi D, et al Neuroendocrine differentiation as an indicator of chemosensitivity and prognosis in nonsmall cell lung cancer. Biomarkers. 2011;16(4):311–320. doi: 10.3109/1354750X.] [[PubMed][Google Scholar]
  • 10. Derks JL, van Suylen RJ, Thunnissen E, et al Chemotherapy for pulmonary large cell neuroendocrine carcinomas: does the regimen matter? Eur Respir J. 2017;496:pii: 1601838. doi: 10.1183/13993003.] [[Google Scholar]
Collaboration tool especially designed for Life Science professionals.Drag-and-drop any entity to your messages.